MSC303
/ Beijing Mabworks Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 02, 2025
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
(clinicaltrials.gov)
- P1/2 | N=12 | Not yet recruiting | Sponsor: Shanghai Changzheng Hospital
New P1/2 trial • Renal Disease
1 to 1
Of
1
Go to page
1